The patient’s peak flow has dropped to 40% of normal, indicating a severe exacerbation of asthma. According to NICE guidelines, admission is recommended if severe attack features persist after a bronchodilator trial. As the peak flow has not improved, hospitalization is necessary.

Administering another nebulizer is not advisable as the patient requires close monitoring and may need multiple nebulizers. Increasing the inhaled steroid dose and sending the patient home is also not recommended as it may lead to adverse outcomes.

Prescribing 40 mg prednisolone for 5 to 7 days is suitable for patients who can be treated at home, but not for this patient with severe asthma requiring inpatient assessment and management.

Antibiotics are only prescribed if the patient has no severe or life-threatening asthma features and shows signs of infection. As the patient’s asthma has not improved despite initial treatment, sending them home with antibiotics is not appropriate.

Understanding Acute Asthma: Symptoms and Severity

Acute asthma is a condition that is typically observed in individuals who have a history of asthma. It is characterized by worsening dyspnea, wheezing, and coughing that doesn’t respond to salbutamol. Acute asthma attacks may be triggered by respiratory tract infections. Patients with acute severe asthma are classified into three categories: moderate, severe, or life-threatening.

Moderate acute asthma is characterized by a peak expiratory flow rate (PEFR) of 50-75% of the best or predicted value, normal speech, a respiratory rate (RR) of less than 25 breaths per minute, and a pulse rate of less than 110 beats per minute. Severe acute asthma is characterized by a PEFR of 33-50% of the best or predicted value, inability to complete sentences, an RR of more than 25 breaths per minute, and a pulse rate of more than 110 beats per minute. Life-threatening acute asthma is characterized by a PEFR of less than 33% of the best or predicted value, oxygen saturation levels of less than 92%, a silent chest, cyanosis or feeble respiratory effort, bradycardia, dysrhythmia or hypotension, and exhaustion, confusion, or coma.

It is important to note that a normal pCO2 in an acute asthma attack indicates exhaustion and should be classified as life-threatening. Understanding the symptoms and severity of acute asthma can help healthcare professionals provide appropriate treatment and management for patients experiencing an acute asthma attack.

A possible diagnosis for this patient is asthma with a mild exacerbation, even if the spirometry test result is negative. Further investigation is necessary, and a fractional exhaled nitric oxide (FeNO) test should be performed to confirm the diagnosis. A FeNO result of >35ppb would be diagnostic for this patient. Another spirometry test is unlikely to provide more clarity. Treatment for this patient includes a salbutamol reliever inhaler and a preventer inhaler. A respiratory referral is not necessary at this time since there are no complications to the diagnosis or treatment. Although the patient is atopic, there are no concerning risk factors in the history or examination that warrant a chest x-ray.

Asthma diagnosis has been updated by NICE guidelines in 2017, which emphasizes the use of objective tests rather than subjective/clinical judgments. The guidance recommends the use of fractional exhaled nitric oxide (FeNO) test, which measures the level of nitric oxide produced by inflammatory cells, particularly eosinophils. Other established objective tests such as spirometry and peak flow variability are still important. All patients aged five and above should have objective tests to confirm the diagnosis. For patients aged 17 and above, spirometry with a bronchodilator reversibility (BDR) test and FeNO test should be performed. For children aged 5-16, spirometry with a BDR test and FeNO test should be requested if there is normal spirometry or obstructive spirometry with a negative BDR test. For patients under five years old, diagnosis should be made based on clinical judgment. The specific points about the tests include a FeNO level of >= 40 ppb for adults and >= 35 ppb for children considered positive, and a FEV1/FVC ratio less than 70% or below the lower limit of normal considered obstructive for spirometry. A positive reversibility test is indicated by an improvement in FEV1 of 12% or more and an increase in volume of 200 ml or more for adults, and an improvement in FEV1 of 12% or more for children.

Treating Infective Exacerbation of Bronchiectasis

When managing a suspected infective exacerbation of bronchiectasis, it is crucial to obtain a sputum culture before initiating antibiotics. However, treatment should not be delayed until the culture results are available. It is also recommended to administer a more extended course of antibiotics than what is typically prescribed for a lower respiratory tract infection.

NICE provides specific guidance on the selection and duration of antibiotics based on the identified organism. Additionally, hospital admission should be considered if there are indications of a more severe illness, such as cyanosis, confusion, respiratory rate exceeding 25 breaths per minute, significant breathlessness, or a temperature of 38°C or higher.

Occupational Asthma and Common Causative Substances

Occupational asthma is a common respiratory condition that affects individuals who are exposed to certain substances in their workplace. The most likely causative substance is isocyanate, which is commonly used in the manufacture of foams and plastics. Other substances that are commonly implicated in occupational asthma include flour/grain, adhesives, metals, resins, colophony, fluxes, latex, animals, aldehydes, and wood dust. Although cotton dust can also be associated with occupational asthma, it is less recognized than isocyanates.

Each year, there are an estimated 1500 to 3000 cases of occupational asthma reported. Symptoms of occupational asthma typically include coughing, wheezing, chest tightness, and shortness of breath. It is important for individuals who work in industries where these substances are present to be aware of the potential risks and to take appropriate precautions to protect their respiratory health.

It is important to note that asbestos exposure is associated with a range of respiratory conditions, including pleural plaques, pleural thickening, pleural effusions, interstitial lung disease, mesothelioma, and lung carcinoma, but not occupational asthma. Silica exposure, which is found in coal dust, can result in pulmonary fibrosis. Simple coal worker’s disease is a nodular interstitial lung disease that is also associated with coal dust exposure.

Antibiotic Prophylaxis for Pertussis

When managing a suspected or confirmed case of pertussis, it is important to offer prophylactic antibiotics to reduce transmission if the case presents within 21 days of onset and a vulnerable contact is present in the household. All household contacts, regardless of age or immunisation status, should be offered antibiotics. Antibiotics may not alter the clinical course of the illness, but they can eliminate the organism from the respiratory tract, reducing person-to-person transmission. Vulnerable contacts include newborn infants, unimmunised or partially immunised infants or children up to 10 years, pregnant women, healthcare workers, immunocompromised individuals, and those with chronic illnesses. The maternal pertussis vaccine programme has been highly effective in preventing disease for infants less than 2 months of age. Therefore, the definition of vulnerable infants has been amended to include unimmunised infants born ≤32 weeks, unimmunised infants born >32 weeks whose mothers did not receive maternal pertussis vaccine after 16 weeks and at least 2 weeks before delivery, and infants aged 2 months or over who are unimmunised or partially immunised. It is important for GPs to understand and implement national guidelines for respiratory problems, including the management of pertussis.

Importance of Thorough Respiratory Examination in Lung Cancer Diagnosis

Pleural effusion and slowly resolving consolidation may indicate lung cancer, requiring urgent referral to a respiratory physician under the two week wait criteria. However, a comprehensive examination is necessary to avoid missing an effusion. Simply auscultating the chest is insufficient. A thorough respiratory examination, including noting any deviation of the trachea, percussion note, and tactile vocal fremitus, can provide important clues and need not significantly prolong the examination time. Failure to perform a thorough examination or investigation of malignancy is a contributing factor to delay in cancer diagnosis, according to the NPSA. In this case, the patient’s smoking history and slow-to-resolve consolidation further support the need for urgent referral and detailed imaging to reveal any underlying cause.

According to NICE guidelines, oral antibiotics should only be prescribed in cases of acute exacerbation of COPD if there is purulent sputum or clinical signs of pneumonia. As this patient doesn’t exhibit these symptoms, prescribing oral antibiotics is not recommended.

Instead, increasing the frequency of inhaled bronchodilators is a suitable step in managing this patient’s acute exacerbation of COPD. The patient’s mild wheeze should improve with this treatment.

NICE recommends a review in 6 weeks if there is no rapid or significant worsening of symptoms. However, if symptoms worsen rapidly or significantly, the patient should be reviewed sooner by the appropriate healthcare provider.

Prescribing oral steroids is appropriate for managing this patient’s acute exacerbation of COPD as it can reduce inflammation and improve symptoms.

It is also appropriate to discuss smoking cessation with the patient, as they are still smoking. However, it should be documented if the patient is not interested in considering smoking cessation. Any opportunity for smoking cessation advice should be utilized.

Acute exacerbations of COPD are a common reason for hospitalization in developed countries. The most common causes of these exacerbations are bacterial infections, such as Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis, as well as respiratory viruses, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators, such as beta adrenergic agonists and muscarinic antagonists, should also be used. Steroid therapy and IV theophylline may be considered, and non-invasive ventilation may be used for patients with type 2 respiratory failure. BiPAP is typically used with initial settings of EPAP at 4-5 cm H2O and IPAP at 10-15 cm H2O.

Treatment options for suboptimal control in COPD patients

To determine the appropriate treatment for suboptimal control in COPD patients, it is recommended to consult the NICE guidance on Chronic obstructive pulmonary disease (CG115). If a patient has suboptimal control despite using a regular short-acting beta 2-agonist (SABA), oral theophylline may be considered at a later stage in the treatment ladder. However, LAMA+LABA should be offered to patients who have spirometrically confirmed COPD, do not have asthmatic features or steroid responsiveness, and remain breathless or have exacerbations despite using a short-acting bronchodilator. It is important to note that adding a regular inhaled steroid is not recommended in the treatment ladder as it is inferior to LABA/ICS combination or LAMA. By following these guidelines, healthcare professionals can provide optimal treatment for COPD patients with suboptimal control.

Acute exacerbations of COPD are a common reason for hospitalization in developed countries. The most common causes of these exacerbations are bacterial infections, such as Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis, as well as respiratory viruses, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators, such as beta adrenergic agonists and muscarinic antagonists, should also be used. Steroid therapy and IV theophylline may be considered, and non-invasive ventilation may be used for patients with type 2 respiratory failure. BiPAP is typically used with initial settings of EPAP at 4-5 cm H2O and IPAP at 10-15 cm H2O.

NICE suggests including an antibiotic only when the sputum shows signs of being purulent.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

If a patient has a known allergy to a sulfa drug like co-trimoxazole, they should avoid taking sulfasalazine.

Sulfasalazine: A DMARD for Inflammatory Arthritis and Bowel Disease

Sulfasalazine is a type of disease modifying anti-rheumatic drug (DMARD) that is commonly used to manage inflammatory arthritis, particularly rheumatoid arthritis, as well as inflammatory bowel disease. This medication is a prodrug for 5-ASA, which works by reducing neutrophil chemotaxis and suppressing the proliferation of lymphocytes and pro-inflammatory cytokines.

However, caution should be taken when using sulfasalazine in patients with G6PD deficiency or those who are allergic to aspirin or sulphonamides due to the risk of cross-sensitivity. Adverse effects of sulfasalazine may include oligospermia, Stevens-Johnson syndrome, pneumonitis/lung fibrosis, myelosuppression, Heinz body anaemia, megaloblastic anaemia, and the potential to color tears and stain contact lenses.

Despite these potential side effects, sulfasalazine is considered safe to use during pregnancy and breastfeeding, making it a viable option for women who require treatment for inflammatory arthritis or bowel disease.

Cognitive Therapy and Breathing Exercises for Hyperventilation Syndrome

Two studies have shown that cognitive therapy and breathing exercises can effectively treat hyperventilation syndrome. This condition often leads to pleuritic chest pain without any apparent cause. During therapy sessions, specific anxiety triggers can be identified and addressed. However, for those with chronic hyperventilation syndrome, cognitive therapy and breathing exercises can provide relief and improve overall quality of life. With these treatments, patients can learn to control their breathing and reduce symptoms of hyperventilation syndrome.

Supraclavicular Lymph Node Enlargement and Malignancy

The right supraclavicular lymph node drains the mid-section of the chest, oesophagus, and lungs. An enlarged and fixed node in this area can indicate malignancy, with the lungs being a common primary site. While glandular fever is a possibility, it is less common in this age group, and the patient is presenting with several alarm symptoms.

Empirically treating with antibiotics is not recommended, as there are no signs of an infected sebaceous cyst, the patient is not feverish, and there is no identified focus for infection. According to NICE guidance, patients with cervical or supraclavicular lymphadenopathy should undergo an urgent chest x-ray.

The NPSA’s thematic review of delayed cancer diagnosis found that 23% of lung cancer cases had diagnostic delays, although not all of these were directly attributable to general practitioners’ actions. Therefore, it is crucial to investigate any supraclavicular lymph node enlargement promptly to rule out malignancy and ensure timely treatment.

The patient is currently in a room with normal air temperature, measuring 38.9º. Their blood pressure is 130/84 mmHg and they appear to be distressed, but not confused. Initial tests indicate that their hemoglobin level is 134 g/l and their platelet count is currently unknown.

Pneumonia is a serious respiratory infection that requires prompt assessment and management. In the primary care setting, the CRB65 criteria are used to stratify patients based on their risk of mortality. Patients with a score of 0 are considered low risk and may be treated at home, while those with a score of 3 or 4 are high risk and require urgent admission to hospital. Antibiotic therapy should be considered based on the patient’s CRP level. In the secondary care setting, the CURB65 criteria are used, which includes an additional criterion of urea > 7 mmol/L. Chest x-rays and blood and sputum cultures are recommended for intermediate or high-risk patients. Management of low-severity pneumonia typically involves a 5-day course of amoxicillin, while moderate to high-severity pneumonia may require dual antibiotic therapy for 7-10 days. Discharge criteria and advice post-discharge are also provided, including information on expected symptom resolution and the need for a repeat chest x-ray at 6 weeks.

If a person has obstructive sleep apnoea (OSA) and is a group 1 driver, they must inform the DVLA if they experience excessive daytime sleepiness (measured by an Epworth score of 11 or higher). However, if the OSA is mild (with an apnoea/hypopnoea index score of 5-15/hour) and doesn’t cause excessive daytime sleepiness, there is no need to notify the DVLA. For those with moderate or severe OSA, the DVLA must be informed and the individual must ensure that their symptoms are under control before driving.

Understanding Obstructive Sleep Apnoea/Hypopnoea Syndrome

Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a condition that causes interrupted breathing during sleep due to a blockage in the airway. This can lead to a range of health problems, including daytime somnolence, respiratory acidosis, and hypertension. There are several predisposing factors for OSAHS, including obesity, macroglossia, large tonsils, and Marfan’s syndrome. Partners of those with OSAHS often complain of excessive snoring and periods of apnoea.

To assess sleepiness, patients may complete the Epworth Sleepiness Scale questionnaire, and undergo the Multiple Sleep Latency Test (MSLT) to measure the time it takes to fall asleep in a dark room. Diagnostic tests for OSAHS include sleep studies (polysomnography), which measure a range of physiological factors such as EEG, respiratory airflow, thoraco-abdominal movement, snoring, and pulse oximetry.

Management of OSAHS includes weight loss and the use of continuous positive airway pressure (CPAP) as a first-line treatment for moderate or severe cases. Intra-oral devices, such as mandibular advancement, may be used if CPAP is not tolerated or for patients with mild OSAHS without daytime sleepiness. It is important to inform the DVLA if OSAHS is causing excessive daytime sleepiness. While there is limited evidence to support the use of pharmacological agents, they may be considered in certain cases.

Understanding Pulmonary Function Tests

Pulmonary function tests are a useful tool in determining whether a respiratory disease is obstructive or restrictive. These tests measure various aspects of lung function, such as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). By analyzing the results of these tests, doctors can diagnose and monitor conditions such as asthma, COPD, pulmonary fibrosis, and neuromuscular disorders.

In obstructive lung diseases, such as asthma and COPD, the FEV1 is significantly reduced, while the FVC may be reduced or normal. The FEV1% (FEV1/FVC) is also reduced. On the other hand, in restrictive lung diseases, such as pulmonary fibrosis and asbestosis, the FEV1 is reduced, but the FVC is significantly reduced. The FEV1% (FEV1/FVC) may be normal or increased.

It is important to note that there are many conditions that can affect lung function, and pulmonary function tests are just one tool in diagnosing and managing respiratory diseases. However, understanding the results of these tests can provide valuable information for both patients and healthcare providers.

Understanding Asbestos Exposure and Mesothelioma

Asbestos is a group of minerals that occur naturally in the environment as bundles of fibres. Exposure to asbestos can lead to various health problems, including asbestosis, lung cancer, mesothelioma, and other cancers. Smokers who are also exposed to asbestos have a higher risk of developing lung cancer. If you suspect that you have been exposed to asbestos, it is important to inform your physician and report any symptoms.

Mesothelioma is a type of cancer that is commonly associated with asbestos exposure. Symptoms of mesothelioma may include chest pain, breathlessness, weight loss, fatigue, and sweats. In some cases, there may be evidence of effusion or pleural thickening on a chest X-ray. An occupational history is important in identifying potential exposure to asbestos.

According to NICE guidelines, individuals aged 40 and over who have unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss should be offered an urgent chest X-ray within two weeks to assess for mesothelioma. This is especially important for those who have been exposed to asbestos or have a history of smoking. Early detection and treatment can improve outcomes for those with mesothelioma.

Initial Management for COPD

The most appropriate initial management for COPD would be a short acting beta agonist or a short acting muscarinic antagonist. According to the Guidelines in Practice summary, a LAMA+LABA combination should be offered to people with spirometrically confirmed COPD who do not have asthmatic features or steroid responsiveness and remain breathless or have exacerbations despite other treatments. LABA+ICS should be considered for those with asthmatic features or steroid responsiveness. Antitussive therapy is not recommended, but a mucolytic can be considered for those with a chronic productive cough. In this breathless patient, a short acting muscarinic antagonist is the better choice. By optimizing non-pharmacological management and relevant vaccinations, patients can improve their symptoms and quality of life.

To ensure proper drug delivery, it is important to use the correct inhaler technique. This involves removing the cap, shaking the inhaler, and taking a slow breath in while delivering the dose. After holding the breath for 10 seconds, it is recommended to wait for approximately 30 seconds before repeating the dose. In this case, the individual should have waited for the full 30 seconds before taking a second dose.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

Overlapping Symptoms of COPD and Other Respiratory Diagnoses

There are several respiratory diagnoses that can present with similar symptoms to COPD, including asthma, bronchiectasis, congestive cardiac failure, and bronchial carcinoma. It is important for healthcare professionals to consider these alternative diagnoses when assessing patients with COPD symptoms.

The basics of history and examination are crucial in forming a list of possibilities and guiding any investigation. In some cases, patients may have a rarer condition such as bronchopulmonary dysplasia or obliterative bronchiolitis.

In the case of this patient, the underlying diagnosis is bronchiectasis caused by childhood pneumonia. This has resulted in chronic sputum production and the presence of clubbing, ruling out asthma, COPD, and congestive cardiac failure. While bronchial carcinoma can also cause finger clubbing and focal chest signs, it is less likely in this case due to the patient’s history and other clinical features. Overall, healthcare professionals should always keep in mind the possibility of an alternative diagnosis when assessing patients with COPD symptoms.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

NICE Guidelines for Referral of Suspected Lung Cancer Patients

The National Institute for Health and Care Excellence (NICE) has issued guidelines for the recognition and referral of suspected lung cancer patients. According to the guidelines, patients aged 40 and over with unexplained haemoptysis should be referred urgently for an appointment within two weeks, even if their chest x-ray is normal. Additionally, patients with two or more unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, or those with persistent or recurrent chest infection, finger clubbing, supraclavicular lymphadenopathy or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis should be offered an urgent chest x-ray within two weeks to assess for lung cancer. These guidelines aim to ensure timely diagnosis and treatment of lung cancer, which is crucial for improving patient outcomes.

The patient has good inhaler technique but needs to wait approximately 30 seconds before repeating the dose. Holding the breath for at least 10 seconds after administering the medication is recommended, but holding it for longer is not necessary. Advising the patient to hold their breath for at least 30 seconds after administering the dose is incorrect.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

Patients who have been diagnosed with anaphylaxis should be referred to a specialist allergy clinic for proper management. In the case of this boy, specialist input and education for his caregivers and school may be necessary. Prescribing a 300 microgram adrenaline injector is not recommended as it is the incorrect dose for his age. Instead, he should be given two 150 microgram adrenaline injectors with appropriate training provided. Referral for patch testing may not be sufficient as more rigorous follow-up is needed after anaphylaxis. Regular antihistamines may be necessary if ongoing symptoms such as urticaria are present, but this is not indicated in the question.

Anaphylaxis is a severe and potentially life-threatening allergic reaction that affects the entire body. It can be caused by various triggers, including food, drugs, and insect venom. The symptoms of anaphylaxis typically develop suddenly and progress rapidly, affecting the airway, breathing, and circulation. Swelling of the throat and tongue, hoarse voice, and stridor are common airway problems, while respiratory wheeze and dyspnea are common breathing problems. Hypotension and tachycardia are common circulation problems. Skin and mucosal changes, such as generalized pruritus and widespread erythematous or urticarial rash, are also present in around 80-90% of patients.

The most important drug in the management of anaphylaxis is intramuscular adrenaline, which should be administered as soon as possible. The recommended doses of adrenaline vary depending on the patient’s age, with the highest dose being 500 micrograms for adults and children over 12 years old. Adrenaline can be repeated every 5 minutes if necessary. If the patient’s respiratory and/or cardiovascular problems persist despite two doses of IM adrenaline, IV fluids should be given for shock, and expert help should be sought for consideration of an IV adrenaline infusion.

Following stabilisation, non-sedating oral antihistamines may be given to patients with persisting skin symptoms. Patients with a new diagnosis of anaphylaxis should be referred to a specialist allergy clinic, and an adrenaline injector should be given as an interim measure before the specialist allergy assessment. Patients should be prescribed two adrenaline auto-injectors, and training should be provided on how to use them. A risk-stratified approach to discharge should be taken, as biphasic reactions can occur in up to 20% of patients. The Resus Council UK recommends a fast-track discharge for patients who have had a good response to a single dose of adrenaline and have been given an adrenaline auto-injector and trained how to use it. Patients who require two doses of IM adrenaline or have had a previous biphasic reaction should be observed for a minimum of 6 hours after symptom resolution, while those who have had a severe reaction requiring more than two doses of IM adrenaline or have severe asthma should be observed for a minimum of 12 hours after symptom resolution. Patients who present late at night or in areas where access to emergency care may be difficult should also be observed for a minimum of 12

Erythema Nodosum and Sarcoidosis: An Overview

Erythema nodosum is a type of inflammation that affects the fat tissue, commonly seen in adult females. It has a higher incidence rate in women, with a female to male ratio of up to three to one. On the other hand, sarcoidosis is a disease that affects multiple systems in the body, characterized by the formation of granulomas. It is more prevalent in adults aged 20-40, with acute cases more common in white patients and chronic cases more common in Afro-Caribbean patients.

Around 30% to 40% of erythema nodosum cases are associated with sarcoidosis. To confirm the diagnosis, chest x-ray, high-resolution CT, and transbronchial biopsy are the main investigations employed. Corticosteroids are the primary treatment for both erythema nodosum and sarcoidosis. With proper management, patients can achieve a good prognosis and quality of life.

Calculating the Wells Score for Pulmonary Embolism

To determine the likelihood of a patient having a pulmonary embolism (PE), healthcare professionals use the Wells score. This score is calculated based on several factors, including clinical examination consistent with deep vein thrombosis, pulse rate, immobilization or recent surgery, past medical history, haemoptysis, cancer, and the likelihood of an alternative diagnosis.

If the two-level Wells score is more than 4 points, hospital admission should be arranged for an immediate computed tomography pulmonary angiogram. If the score is 4 or lower, a D-dimer blood test should be arranged. A negative result may indicate an alternative diagnosis, while a positive result should be managed the same way as a two-level Wells score of more than 4.

It is important to note that HASBLED and CHADS2VASC scoring are used in the management of patients with atrial fibrillation, not pulmonary embolism. By using the Wells score, healthcare professionals can quickly and accurately determine the likelihood of a patient having a PE and provide appropriate treatment.

Diagnostic Tests for COPD

In addition to spirometry, it is recommended that patients with COPD undergo several diagnostic tests at the time of diagnosis. These tests include a chest x-ray to rule out other potential lung pathologies, a full blood count to assess for anemia or polycythemia, and a calculation of body mass index.

Depending on the patient’s history and examination findings, other diagnostic tests may be necessary. For example, if asthma is suspected, serial peak flow measurements may be indicated. If signs or symptoms of cor pulmonale are present, an ECG or echocardiogram may be necessary. By conducting these diagnostic tests, healthcare professionals can accurately diagnose and manage COPD in their patients.

British Thoracic Society Guidelines for Asthma Management

The British Thoracic Society has provided guidelines for the management of asthma, which is a potentially life-threatening condition. To categorize the severity of an acute asthma attack and guide management, parameters such as respiratory rate, pulse rate, and peak flow rate are essential. For instance, a peak flow rate of just over 33% of the patient’s best is considered an ‘acute severe’ attack.

An ‘acute severe’ attack is defined as any one of the following: peak expiratory flow rate of 33-50% best or predicted, respiratory rate of 25 or more per minute, heart rate of 110 or more beats per minute, or inability to complete sentences in one breath. On the other hand, a ‘life-threatening’ attack is defined as any of the following features in a patient with severe asthma: peak expiratory flow rate <33% best or predicted, oxygen saturation less than 92%, PaO2 of <8 kPa, normal PaCO2, silent chest, cyanosis, poor respiratory effort, arrhythmia, or exhaustion/altered conscious level. It is crucial to follow these guidelines to ensure appropriate management of asthma and prevent life-threatening complications.

If asthma is well controlled, it is advisable to reduce the treatment, as per the guidelines of the British Thoracic Society.

Stepping Down Asthma Treatment: BTS Guidelines

The British Thoracic Society (BTS) recommends that asthma treatment should be reviewed every three months to consider stepping down treatment. However, the guidelines do not suggest a strict move from one step to another but rather advise taking into account the duration of treatment, side-effects, and patient preference. When reducing the dose of inhaled steroids, the BTS suggests doing so by 25-50% at a time.

Patients with stable asthma may only require a formal review once a year. However, if a patient has recently had an escalation of asthma treatment, they are likely to be reviewed more frequently. It is important to follow the BTS guidelines to ensure that patients receive the appropriate level of treatment for their asthma and to avoid unnecessary side-effects.

Treatment Algorithm for COPD Patients

Page 9 of the NICE reference guide on Chronic obstructive pulmonary disease (CG101) provides an overview of the treatment algorithm for patients with COPD. If a patient has inadequately controlled symptoms despite using a regular short-acting beta agonist and an FEV1 of greater or equal to 50%, the next options are to add in a long-acting beta agonist or a long-acting muscarinic antagonist. In both cases, the short-acting beta agonist can continue to be used as required. Therefore, the correct answer from the list of options is to add in a regular long-acting muscarinic antagonist.

If the patient has an FEV1 <50%, the treatment choice would alter again with the option of using a long-acting beta agonist/inhaled corticosteroid combination inhaler. It is important to follow the treatment algorithm to ensure that patients receive the appropriate treatment for their COPD symptoms. Proper management of COPD can improve a patient's quality of life and reduce the risk of exacerbations.

Assessment and Severity of Acute Asthma

Assessment and severity of acute asthma are common topics in exams. The British Thoracic Society provides clear guidance on the assessment and management of acute asthma, which should be familiar to healthcare professionals.

Indicators of acute severe asthma include a peak expiratory flow rate of 33-50% of best or predicted, a respiratory rate of 25 or greater, a heart rate of 110/min or greater, or an inability to complete sentences in one breath. The aim of oxygen therapy is to maintain SpO2 94-98%.

In the case of this man, the only indicator of an acute severe asthma attack is a respiratory rate of >25. If any of these features persist after initial treatment, the patient should be admitted. It is important for healthcare professionals to be aware of these indicators and to follow the appropriate management guidelines to ensure the best possible outcome for the patient.

Tests for Diagnosing Asthma

The diagnosis of asthma can be challenging, but there are several tests available to help healthcare professionals make an accurate diagnosis. One such test is peak expiratory flow (PEF) variability, which involves measuring PEF readings four or more times per day. A variation of more than 20% is highly suggestive of asthma, although some patients may have lower variability.

Other tests include fractional exhaled nitric oxide (FeNO), spirometry, and bronchodilator reversibility. FeNO levels of 40 parts per billion or more are considered positive for asthma in patients aged 17 and over. Obstructive spirometry, indicated by a forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio of less than 70%, is also a positive test. Bronchodilator reversibility is positive if there is an improvement in FEV1 of 12% or more and an increase in volume of 200 ml or more in patients aged 17 and over.

It is important to note that there are caveats and age limitations to these tests, and healthcare professionals should refer to the latest NICE guidance NG80 for more detailed information.

Varenicline: An Effective Anti-Smoking Agent

Varenicline, also known as Champix, is an oral medication that helps individuals quit smoking. It has a dual action, reducing the craving for cigarettes and making smoking less pleasurable. Clinical trials have shown that Varenicline is more effective than both bupropion and placebo.

The medication is prescribed for 12 weeks initially, and if cravings persist, a further 12-week course may be prescribed. Varenicline has been proven to be an effective tool in helping individuals quit smoking and can be a valuable addition to a comprehensive smoking cessation program.

Management of Acute Asthma Symptoms

Several important points should be considered when managing a patient with acute asthma symptoms. Firstly, it is important to note if the patient is already taking preventative treatment for asthma. If they are, an increase in the use of their salbutamol inhaler may indicate that their symptoms are worse than usual. Secondly, recent viral infections can trigger asthma symptoms. Additionally, the absence of discoloured thick phlegm and fever makes it less likely that the patient has a bacterial infection and therefore doesn’t require antibiotic therapy.

When managing acute asthma symptoms, it is important to note that changing inhalers may not be appropriate at this stage. Oxygen therapy is not necessary if the patient’s oxygen saturations are above 94% in air. A nebuliser may not be indicated if the patient’s breathing rate is not compromised and they are clinically stable. It may be beneficial to initially try a salbutamol inhaler before ipratropium bromide. These considerations can help guide the management of acute asthma symptoms.

Polycythaemia can be a long-term complication of COPD that may be detected through a full blood count. This condition is caused by chronic hypoxia, which triggers the kidneys to produce more erythropoietin and increase haemoglobin levels. Thrombocytopenia, on the other hand, is a reduction in platelet count that can be caused by various factors such as medication side effects, vitamin deficiencies, or disseminated intravascular coagulation. Conversely, thrombocythemia, or an elevated platelet count, can be caused by inflammation, malignancy, or infection. Leukopenia, or a decrease in white blood cells, can be a result of acute infection or serious conditions like HIV or cancer. Finally, anaemia, or a decrease in haemoglobin concentration, can be caused by deficiencies in iron, vitamin B12, or folic acid.

Understanding COPD: Symptoms and Diagnosis

Chronic obstructive pulmonary disease (COPD) is a common medical condition that includes chronic bronchitis and emphysema. Smoking is the leading cause of COPD, and patients with mild disease may only need occasional use of a bronchodilator, while severe cases may result in frequent hospital admissions due to exacerbations. Symptoms of COPD include a productive cough, dyspnea, wheezing, and in severe cases, right-sided heart failure leading to peripheral edema.

To diagnose COPD, doctors may recommend post-bronchodilator spirometry to demonstrate airflow obstruction, a chest x-ray to check for hyperinflation, bullae, and flat hemidiaphragm, and to exclude lung cancer. A full blood count may also be necessary to exclude secondary polycythemia, and body mass index (BMI) calculation is important. The severity of COPD is categorized using the FEV1, with a ratio of less than 70% indicating airflow obstruction. The grading system has changed following the 2010 NICE guidelines, with Stage 1 – mild now including patients with an FEV1 greater than 80% predicted but with a post-bronchodilator FEV1/FVC ratio of less than 0.7. Measuring peak expiratory flow is of limited value in COPD, as it may underestimate the degree of airflow obstruction.

In summary, COPD is a common condition caused by smoking that can result in a range of symptoms and severity. Diagnosis involves various tests to check for airflow obstruction, exclude lung cancer, and determine the severity of the disease.

Management of Moderate COPD

Patients with an FEV1/FVC ratio <0.70 and an FEV1 of 50-79% predicted are classified as having stage 2 moderate COPD. The initial management for such patients would be a short acting beta agonist or a short acting muscarinic antagonist. However, if symptoms persist, NICE recommends the use of a long acting beta agonist plus a long acting muscarinic antagonist. In cases where a long acting muscarinic antagonist is given, the short acting muscarinic antagonist should be stopped.

Inhaled corticosteroids alone are not recommended for moderate COPD. Instead, they should be used in combination with a long acting beta agonist as a second line treatment for patients with an FEV1 < 50%. Maintenance use of oral corticosteroid therapy in COPD is not normally recommended. Antitussive therapy is also not recommended.

If a patient with COPD continues to smoke, it is not advisable to provide them with azithromycin prophylaxis. Instead, they should be offered smoking cessation. The use of high-dose inhaled corticosteroids is no longer recommended due to the increased risk of infections such as pneumonia. Long-term oral corticosteroids should only be used at low doses and on the advice of the respiratory team. Beta-carotene supplements are not recommended for the management of COPD due to limited evidence of their effectiveness.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Understanding Acute Asthma: Symptoms and Severity

Acute asthma is a condition that is typically observed in individuals who have a history of asthma. It is characterized by worsening dyspnea, wheezing, and coughing that doesn’t respond to salbutamol. Acute asthma attacks may be triggered by respiratory tract infections. Patients with acute severe asthma are classified into three categories: moderate, severe, or life-threatening.

Moderate acute asthma is characterized by a peak expiratory flow rate (PEFR) of 50-75% of the best or predicted value, normal speech, a respiratory rate (RR) of less than 25 breaths per minute, and a pulse rate of less than 110 beats per minute. Severe acute asthma is characterized by a PEFR of 33-50% of the best or predicted value, inability to complete sentences, an RR of more than 25 breaths per minute, and a pulse rate of more than 110 beats per minute. Life-threatening acute asthma is characterized by a PEFR of less than 33% of the best or predicted value, oxygen saturation levels of less than 92%, a silent chest, cyanosis or feeble respiratory effort, bradycardia, dysrhythmia or hypotension, and exhaustion, confusion, or coma.

It is important to note that a normal pCO2 in an acute asthma attack indicates exhaustion and should be classified as life-threatening. Understanding the symptoms and severity of acute asthma can help healthcare professionals provide appropriate treatment and management for patients experiencing an acute asthma attack.

Diagnostic Thresholds for Asthma Tests

FeNO tests, which measure nitric oxide levels in breath, are used to detect lung inflammation and asthma. The positive test threshold for adults is 40 ppb, while for children and young people it is 35 ppb or more. Obstructive spirometry, which measures FEV1/FVC ratio, has a positive test threshold of less than 70% for all age groups. Peak flow variability, which measures the difference between the highest and lowest peak flow readings, has a positive test threshold of over 20% for all age groups. While a peak flow variability of 50% is indicative of asthma, a threshold of 20% is used for diagnosis. It is important to note that some GP practices may not have access to FeNO testing equipment, which is a relatively new development in asthma diagnosis. Familiarizing oneself with these diagnostic thresholds is crucial in the context of NICE guidance, as the RCGP may test changes to guidance.

Cough Characteristics and Associated Conditions

A bovine cough, resembling the sound of cattle, is often heard in cases of recurrent laryngeal nerve palsy, which is commonly caused by lung cancer. Bronchiectasis, on the other hand, is characterized by the production of large amounts of purulent sputum. In women, chronic cough without airways disease is more common, and reflux is often the underlying cause. In cases of chronic obstructive pulmonary disease (COPD), a productive cough is typical, but it may become non-productive in the end stages of the disease. These distinct cough characteristics can provide valuable clues in diagnosing and managing various respiratory conditions.

Consideration of Alpha 1-Antitrypsin Deficiency in a Young Smoker with COPD

This patient’s young age, symptoms, chest x-ray findings, and spirometry results suggest the possibility of alpha 1-antitrypsin deficiency, a genetic condition that can cause pulmonary disease and liver disease. As a smoker, this patient is at increased risk for COPD, but the early onset of the disease raises suspicion for an underlying genetic cause. Additionally, the family history supports the consideration of alpha 1-antitrypsin deficiency, which is inherited in an autosomal dominant pattern.

To confirm the diagnosis, serum alpha 1-antitrypsin levels would be the most appropriate blood investigation. Other blood tests, such as ACE levels for sarcoidosis, copper and ceruloplasmin levels for Wilson’s disease, ferritin levels for hemochromatosis, and rheumatoid factor for rheumatoid arthritis, are not likely to be helpful in this case.

It is important to consider alpha 1-antitrypsin deficiency in young patients with COPD, especially those with a family history of the condition. Early diagnosis and treatment can help prevent further lung and liver damage.

Process of Elimination in Tricky Questions

When faced with a tricky question, it is important to stay calm and think through the options. One useful technique is the process of elimination. For example, in a question about the best antibiotic for a patient with a penicillin allergy who is taking aminophylline, you can immediately eliminate options that contain penicillin. Macrolides and ciprofloxacin can interact with aminophylline, increasing its plasma concentration, so you can eliminate those options as well. By process of elimination, you can arrive at the best answer, which in this case is doxycycline. Practicing this approach can help you tackle tricky questions and improve your performance in exams. Remember to take your time, read the question carefully, and eliminate options that do not fit the criteria.

Referral and Assessment Guidelines for Lung Cancer

Persistent haemoptysis, superior vena caval obstruction, and stridor are all red flags for possible lung cancer and require immediate referral to a cancer specialist. In addition, NICE NG12 recommends an urgent chest X-ray within two weeks for individuals aged 40 and over who have unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, especially if they have a history of smoking. For those with persistent or recurrent chest infections, finger clubbing, supraclavicular or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis, an urgent chest X-ray should also be considered. Early detection and referral can improve outcomes for individuals with lung cancer.

Mycoplasma Infection and Treatment

The history of epidemic pneumonia, slow onset of symptoms, and erythema multiforme suggest the possibility of mycoplasma infection. In mycoplasma, the appearance on CXR is often worse than clinical examination, and the presence of cold agglutins or rising mycoplasma serology can confirm the diagnosis. Treatment with clarithromycin or erythromycin for 7-14 days is recommended, with doxycycline as an alternative and quinolones as an option.

Pertussis: Symptoms and Complications

Pertussis, also known as whooping cough, is a respiratory condition that can manifest at any time. Patients with pertussis experience paroxysms of coughing during waking hours, but unlike many respiratory conditions, sleep is usually undisturbed. An inspiratory whoop may not be present, and complete apnoea may occur. A useful feature in the history taking is that patients typically do not experience disturbed sleep. Additionally, there is typically a lymphocytosis present.

It is important to note that asthma in the mother is not a contraindication for pertussis. However, complications can arise from the disease, such as hemiplegia and convulsions.

For non-smoking men, successful drainage can lead to a decrease in the risk of pneumothorax recurrence. The CAA recommends waiting for 2 weeks after drainage before flying if there is no remaining air. The British Thoracic Society previously advised against air travel for 6 weeks, but now suggests waiting only 1 week after a follow-up x-ray.

Pneumothorax, a condition where air enters the space between the lung and chest wall, can be managed according to guidelines published by the British Thoracic Society (BTS) in 2010. The guidelines differentiate between primary pneumothorax, which occurs without underlying lung disease, and secondary pneumothorax, which does have an underlying cause. For primary pneumothorax, patients with a small amount of air and no shortness of breath may be discharged, while those with larger amounts of air or shortness of breath may require aspiration or chest drain insertion. For secondary pneumothorax, chest drain insertion is recommended for patients over 50 years old with large amounts of air or shortness of breath, while aspiration may be attempted for those with smaller amounts of air. Patients with persistent or recurrent pneumothorax may require video-assisted thoracoscopic surgery. Discharge advice includes avoiding smoking to reduce the risk of further episodes and avoiding scuba diving unless the patient has undergone surgery and has normal lung function.

Symptoms and Risk Factors for COPD

A diagnosis of COPD should be considered in patients who are over 35 years old and have a risk factor, typically smoking. If a patient presents with one or more of the following symptoms, they should be evaluated for COPD: exertional breathlessness, chronic cough, regular sputum production, frequent winter bronchitis, or wheeze. However, chest pain and haemoptysis are uncommon and should lead to consideration of an alternative diagnosis. It is important to recognize these symptoms and risk factors in order to diagnose and treat COPD early, which can improve patient outcomes and quality of life.

An ECG and baseline liver function tests should be performed prior to initiating azithromycin to ensure there is no prolonged QT interval and to establish a baseline for liver function. As the liver function tests in the question stem were normal, the most suitable option would be to conduct an ECG.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Asthma Assessment and Management in Primary Care

Asthma is a chronic respiratory condition that affects millions of people worldwide. In primary care, patients with acute asthma are stratified into moderate, severe, or life-threatening categories based on their symptoms. For moderate asthma, treatment involves the use of beta 2 agonists such as salbutamol, either nebulized or via a spacer. If the patient’s peak expiratory flow rate (PEFR) is between 50-75%, prednisolone 40-50 mg may also be prescribed.

For severe asthma, admission may be necessary, and oxygen should be given to hypoxemic patients to maintain a SpO2 of 94-98%. Beta 2 agonists such as salbutamol, either nebulized or via a spacer, and prednisolone 40-50 mg should also be administered. If there is no response to treatment, admission is recommended.

In life-threatening asthma cases, immediate admission should be arranged through a 999 call. Oxygen should be given to hypoxemic patients to maintain a SpO2 of 94-98%, and nebulized beta 2 agonists (e.g. Salbutamol) + ipratropium should be administered. Prednisolone 40-50 mg or IV hydrocortisone 100 mg may also be prescribed.

In summary, the management of asthma in primary care involves stratifying patients based on their symptoms and administering appropriate treatment based on their category. It is important to closely monitor patients and adjust treatment as necessary to prevent exacerbations and improve their quality of life.

Diagnosis and Treatment of Asthma in Adults

In adults, the diagnosis of asthma can be challenging, especially when there is diagnostic uncertainty or when both asthma and chronic obstructive pulmonary disease (COPD) are present. The British Thoracic Society recommends a 6-8 week treatment trial of inhaled beclomethasone (or equivalent) twice daily for patients with significant airflow obstruction. However, in patients with suspected inhaled corticosteroid resistance, a two-week treatment trial of oral prednisolone 30 mg daily is preferred.

To help identify asthma, clinicians should assess FEV1 (or PEF) and/or symptoms before and after 400mcg inhaled salbutamol. A >400ml improvement in FEV1 to either b2 agonists or corticosteroid treatment strongly suggests underlying asthma. Serial peak flow measurements showing 20% or greater diurnal or day-to-day variability can also be used to help diagnose asthma.

NICE NG115 further clarifies that a large response to bronchodilators or oral prednisolone (over 400 ml) can also help identify asthma. Clinically significant COPD is not present if the FEV1 and FEV1/FVC ratio return to normal with drug therapy. In cases of diagnostic uncertainty, a combination of these findings can be used to help diagnose asthma and guide treatment decisions.